AC
EDSA icon

Armistice Capital’s Edesa Biotech EDSA Stock Holding History

Armistice Capital’s Portfolio EDSA Stock Details EDSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-146,182
Closed -$1.65K – 213
2022
Q2 		$1.65K Sell
146,182
-61,902
-30% -$912K 0.03% 118
2022
Q1 		$4.33M Buy
+208,084
New +$5.76M 0.08% 85

Other funds holding EDSA

CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return

Armistice Capital's EDSA Position: Q3 2022 in Review

Armistice Capital sold out of Edesa Biotech (EDSA) in Q3 2022, closing a stake of 146,182 shares — an estimated $1.65K sold.

Armistice Capital first reported a position in EDSA in Q1 2022 and held it in 2 quarters. The position peaked at $4.33M in Q1 2022. 21 funds tracked by Wall St. Rank hold EDSA as of Q3 2022.

  • Armistice Capital reported no remaining Edesa Biotech position as of Q3 2022 after selling out during the quarter.
  • Armistice Capital sold 146,182 Edesa Biotech shares in Q3 2022, an estimated $1.65K.
  • Armistice Capital first reported a position in Edesa Biotech in Q1 2022 and held it in 2 quarters.
  • Armistice Capital's Edesa Biotech position peaked at $4.33M in Q1 2022.
  • 21 funds tracked by Wall St. Rank held Edesa Biotech as of Q3 2022.

Based on Armistice Capital's 13F filing for Q3 2022, filed 14 Nov 2022.